Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation

Experimental Neurology

Volumn 248, Issue , 2013, Pages 451-456

  Rozenstein Tsalkovich, Lea ^a   Grigoriadis, Nikolaos ^b   Lourbopoulos, Athanasios ^b   Nousiopoulou, Evangelia ^b   Kassis, Ibrahim ^a   Abramsky, Oded ^a   Karussis, Dimitrios ^a   Rosenmann, Hanna ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Alzheimer's disease; Immunotherapy; Neurofibrillary tangles; Phosphorylated tau; Tau protein; Tauopathy

Indexed keywords

PHOSPHOPROTEIN; TAU PROTEIN;

ADULT ANIMAL; AGE; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; DRUG SAFETY; EMULSION; HISTOPATHOLOGY; IMMUNIZATION; IMMUNOTHERAPY; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ALZHEIMER'S-DISEASE; IMMUNOTHERAPY; NEUROFIBRILLARY-TANGLES; PHOSPHORYLATED-TAU; TAU PROTEIN; TAUOPATHY;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; ENCEPHALITIS; IMMUNIZATION; IMMUNOTHERAPY; NEUROFIBRILLARY TANGLES; NEURONS; PHOSPHORYLATION; TAU PROTEINS; TAUOPATHIES;

EID: 84882793431     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.07.006     Document Type: Article

References (21)

1. Asuni A.A., Boutajangout A., Quartermain D., Sigurdsson E.M. Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 2007, 27:9115-9129.
2. Banks W.A. Are the extracellular [correction of extracelluar] pathways a conduit for the delivery of therapeutics to the brain?. Curr. Pharm. Des. 2004, 10:1365-1370.
3. Bi M., Ittner A., Ke Y.D., Gotz J., Ittner L.M. Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 2011, 6:e26860.
4. Boettger M.K., Weishaupt A., Geis C., Toyka K.V., Sommer C. Mild experimental autoimmune encephalitis as a tool to induce blood-brain barrier dysfunction. J Neural Transm 2010, 117:165-169.
5. Boimel M., Grigoriadis N., Lourbopoulos A., Haber E., Abramsky O., Rosenmann H. Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp. Neurol. 2010, 224:472-485.
6. Boutajangout A., Quartermain D., Sigurdsson E.M. Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J. Neurosci. 2010, 30:16559-16566.
7. Boutajangout A., Ingadottir J., Davies P., Sigurdsson E.M. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem. 2011, 118:658-667.
8. Castillo-Carranza D., Lasagna-Reeves C., Estes D., Barrett A., Dineley K., Jackson G., Kayed R. Modulation of tau oligomers by passive vaccination. Soc. Neurosci. Abstr. 2010, 347:11.
9. Chai X., Wu S., Murray T.K., Kinley R., Cella C.V., Sims H., Buckner N., Hanmer J., Davies P., O'Neill M.J., Hutton M.L., Citron M. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J. Biol. Chem. 2011, 286:34457-34467.
10. Fabian R.H. Uptake of antineuronal IgM by CNS neurons: comparison with antineuronal IgG. Neurology 1990, 40:419-422.
11. Furlan R., Brambilla E., Sanvito F., Roccatagliata L., Olivieri S., Bergami A., Pluchino S., Uccelli A., Comi G., Martino G. Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain 2003, 126:285-291.
12. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., Orgogozo J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
13. Kaye J.F., Kerlero de Rosbo N., Mendel I., Flechter S., Hoffman M., Yust I., Ben-Nun A. The central nervous system-specific myelin oligodendrocytic basic protein (MOBP) is encephalitogenic and a potential target antigen in multiple sclerosis (MS). J. Neuroimmunol. 2000, 102:189-198.
14. Makinodan T., Albright J.W., Good P.I., Peter C.P., Heidrick M.L. Reduced humoral immune activity in long-lived old mice: an approach to elucidating its mechanisms. Immunology 1976, 31:903-911.
15. Monsonego A., Imitola J., Petrovic S., Zota V., Nemirovsky A., Baron R., Fisher Y., Owens T., Weiner H.L. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:5048-5053.
16. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
17. Rosenmann H. Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies. Curr. Alzheimer Res. 2013, 18:217-228.
18. Rosenmann H., Grigoriadis N., Karussis D., Boimel M., Touloumi O., Ovadia H., Abramsky O. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch. Neurol. 2006, 63:1459-1467.
19. Rosenmann H., Grigoriadis N., Eldar-Levy H., Avital A., Rozenstein L., Touloumi O., Behar L., Ben-Hur T., Avraham Y., Berry E., Segal M., Ginzburg I., Abramsky O. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp. Neurol. 2008, 212:71-84.
20. Salloway S., Sperling R., Gilman S., Fox N.C., Blennow K., Raskind M., Sabbagh M., Honig L.S., Doody R., van Dyck C.H., Mulnard R., Barakos J., Gregg K.M., Liu E., Lieberburg I., Schenk D., Black R., Grundman M. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 73:2061-2070.
21. Troquier L., Caillierez R., Burnouf S., Fernandez-Gomez F., Grosjean M., Zommer N., Sergeant N., Schraen-Maschke S., Blum D., Buée L. Targeting phospho-Ser422 by active tau immunotherapy in the THY-22Tau mouse model: a suitable therapeutic approach. Curr. Alzheimer Res. 2012, 9:397-405.